Stem Cell Implants That Restore Insulin Production in Diabetes Patients

The project was funded with EUR 6,200,000 in EU contribution across 7 partners. Licensing terms would need to be negotiated with the coordinator (Vrije Universiteit Brussel) and relevant industry partners. Cell therapy manufacturing and encapsulation device production involve significant scale-up costs typical for clinical-grade biologics.

The project developed manufacturing protocols for clinical studies using human embryonic stem cells as the starting material. Human beta cell preparations were produced with quality-control data for both preclinical models and clinical transplants. Scaling from clinical-grade batches to commercial production would require additional manufacturing development with GMP-certified partners.

The consortium includes 3 industry partners and 1 SME across 6 countries, suggesting IP is likely distributed among multiple parties. Key IP areas include the encapsulation device technology, the stem cell differentiation protocols, the screening assay, and the biodegradable microparticle formulations. Contact the coordinator for specific licensing availability.

As a cell therapy product using human embryonic stem cells in an implantable device, this falls under Advanced Therapy Medicinal Products (ATMP) regulation in Europe. The project conducted pilot clinical studies (VCTM-01 trial) and generated QC data meeting clinical transplant standards, which provides a regulatory foundation for further clinical development.

The project reached clinical pilot stage — human beta cell grafts with QC data were prepared for transplants in a subgroup of Type 1 diabetes patients who completed the VCTM-01 trial. Preclinical models were used to guide clinical protocol modifications. Based on available project data, further efficacy studies would be needed before broad clinical deployment.

The project developed state-of-the-art methods and markers to investigate implant biology and monitor host immune and innate reactivity. These tools help understand the basis for metabolic outcome and identify targets for improvement, which is valuable for any company developing cell-based diabetes therapies or immune monitoring solutions.

Yes. The screening assay using hu-iPS-derived beta cells was designed to identify compounds that positively affect functional human beta cell mass. Based on deliverable descriptions, this assay establishes proof-of-principle for equivalency with pancreatic human beta cells and can screen compound libraries independently as a drug discovery tool.